Our findings further expand our knowledge of extensive PITPNM3 expression and its functional role in the tumor microenvironment, suggesting that CCL18-PITPNM3 could be an attractive therapeutic target in the tumor microenvironment. This evidence concerns the gene CCL18 and neoplasm.